论文部分内容阅读
目的 探讨血清CA12 5半衰期在卵巢上皮性癌中的预后价值。方法 回顾性分析 30例卵巢上皮性癌患者在化疗过程中血清CA12 5半衰期值 (t1/ 2 )与生存时间的关系。结果 血清CA12 5半衰期值 (t1/ 2 )≤ 2 0天组的中位生存时间为 36个月 ,t1/ 2 >2 0天组的中位生存时间为 10个月 ,两者存活率存在极显著差异 (P =0 0 0 0 1) ,经过 2年以上随访 ,t1/ 2 ≤ 2 0天组中完全缓解率为 84 2 %。t1/ 2 >2 0天组中完全缓解率为 2 7 3 % ,两者存在极显著差异 (P =0 0 0 1)。多因素生存分析表明 :CA12 5半衰期和细胞分级、残余瘤灶大小均是独立的预后因素。结论 CA12 5半衰期可作为一反映化疗敏感性的临床指标 ,有较好的早期预测疗效价值 ,是一独立预后因素
Objective To investigate the prognostic value of serum CA12 5 half-life in epithelial ovarian cancer. Methods The relationship between serum half-life of CA12 5 (t1 / 2) and survival time in 30 patients with epithelial ovarian cancer during chemotherapy was retrospectively analyzed. Results The median survival time of serum CA12 5 ≤ t1 was 36 months, and the median survival time of t1 / 2> 20 days was 10 months (P = 0 0 0 0 1). After 2 years of follow-up, the complete remission rate was 84 2% in the t1 / 2 ≤ 20 days group. The complete remission rate was 27.3% in t1 / 2> 20 days group, with significant difference (P = 0 0 0 1). Multivariate survival analysis showed that the half-life of CA12 5, cell grade and residual tumor size were independent prognostic factors. Conclusion The half-life of CA12 5 can be used as a clinical indicator reflecting the sensitivity of chemotherapy. It has a good prognostic value in early stage and is an independent prognostic factor